[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hereditary-leiomyomatosis-and-renal-cell-carcinoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hereditary-leiomyomatosis-and-renal-cell-carcinoma":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,48],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100648145","phase-1-mercaptopurine-for-the-treatment-of-hereditary-leiomyomatosis-and-renal-cell-carcinoma-hlrcc-uterinecutaneous-leiomyomas-and-kidney-cancer-100648145",false,"NCT07716735","Mercaptopurine for the Treatment of Hereditary Leiomyomatosis and Renal Cell Carcinoma (HLRCC), Uterine\u002FCutaneous Leiomyomas, and Kidney Cancer","Mercaptopurine (6-MP) for the Treatment of Manifestations of Hereditary Leiomyomatosis and Renal Cell Carcinoma (HLRCC)","Inclusion Criteria:\n\n* Age ≥ 18\n* Disease-causing, germline FH mutation including variants considered either:\n\n  * a) Pathogenic\u002Flikely pathogenic OR\n  * b) variants of unknown significance (VUS) with immunohistochemical staining showing loss of FH or high 2-SC expression in tumor tissue\n* Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤ 1\n* Thiopurine S-methyltransferase (TPMT) and NUDT15 homozygous, wild-type genotype\n\n  * TPMT\\*1\u002FTPMT\\*1 and NUDT15\\*1\u002F NUDT15\\*1\n* Calculated creatinine clearance ≥ 30 milliliters per minute (mL\u002Fmin) per the Cockcroft and Gault formula OR serum creatinine \\\u003C 1.5 x upper limit of normal (ULN)\n* Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \\\u003C 3 x ULN (\\\u003C 5 x ULN if liver metastases are present)\n* Total bilirubin \\\u003C 1.5 x ULN (except subjects with Gilbert Syndrome, who can have total bilirubin up to 3.0 mg\u002FdL)\n* Albumin ≥ 2.2 mg\u002FdL\n* White blood cells (WBC) \\> 2,000\u002Fmm\\^3\n* Hemoglobin (Hb) ≥ 9\n* Neutrophils \\> 1,500\u002Fmm\\^3\n* Platelets \\> 100,000\u002Fmm\\^3\n* Inclusion into ≥ 1 of the following symptomatic, disease states listed below:\n\n  * Inclusion allows entry into that cohort for efficacy assessments. Patients can be in ≥ 1 cohort if they have more than one disease manifestation fitting the below criteria. If a patient fits inclusion\u002Fexclusion into one cohort and has disease manifestations that are excluded from another cohort, they can still participate in the trial but will not be assessed for efficacy for that specific disease manifestation\n* KIDNEY CANCER COHORT: Advanced, metastatic kidney cancer disease\n* KIDNEY CANCER COHORT: Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria\n* KIDNEY CANCER COHORT: ≥ 1 lines of systemic therapy (not considering adjuvant)\n* UTERINE FIBROIDS COHORT: Age ≥ 18\n* UTERINE FIBROIDS COHORT: Female biologic sex\n* UTERINE FIBROIDS COHORT: Any pre-menopausal patient\n* UTERINE FIBROIDS COHORT: Fibroid-associated symptoms including symptomatic menorrhagia and\u002For pelvic pain\u002Fpressure\n* UTERINE FIBROIDS COHORT: Estimated ≤ 15-week uterus by bimanual exam OR by radiographic parameters (≤ 10 cm max dimension of largest fibroid or estimated weight ≤ 400 g)\n* UTERINE FIBROIDS COHORT: Be willing to use non hormonal contraception if needed\n* CUTANEOUS LEIOMYOMAS COHORT: ≥ 5 cutaneous leiomyomas\n* CUTANEOUS LEIOMYOMAS COHORT: Leiomyoma-associated pain or paresthesia causing weekly pain ≥ 4\u002F10 on a pain scale\n\nExclusion Criteria:\n\n* Absolute contraindication to the use of contrast-enhanced imaging for efficacy assessment. If moderate allergy, patients could be allowed if pre-medication can be given to limit adverse reactions. (\\*Not relevant for skin-only cohort)\n* Presence of untreated brain metastases. Treated brain metastases must be stable for 4 weeks after treatment, have no clinical symptoms, and not be on corticosteroids \\> 10 mg\u002Fday of prednisone-equivalent \\> 2 weeks prior to treatment. Patients with known leptomeningeal metastases are excluded\n* Any active or recent history of a known or suspected autoimmune disease or recent history of a syndrome that required systemic corticosteroids (\\> 10 mg daily prednisone equivalent) or immunosuppressive medications within 14 days prior to first dose of study drug. An exception is allowed for syndromes which would not be expected to recur in the absence of an external trigger. Subjects with vitiligo or type I diabetes mellitus or residual hypothyroidism due to autoimmune thyroiditis only requiring hormone replacement are permitted to enroll. Inhaled steroids and adrenal replacement steroid doses \\> 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease\n* History of myocarditis or congestive heart failure (as defined by New York Heart Association Functional Classification III or IV), as well as unstable angina, serious uncontrolled cardiac arrhythmia, uncontrolled infection, or myocardial infarction 6 months prior to study entry\n* Known medical condition that, in the investigator's opinion, would increase the risk associated with study participation or interfere with the interpretation of safety results\n* Individuals who are pregnant; negative serum pregnancy tests in patients of childbearing potential and consent to an effective contraceptive method (if needed Centers for Disease Control and Prevention \\[CDC\\] guidelines provided) until a minimum of 30 days after cessation of therapy\n* Individuals who wish to continue actively breast-feeding must agree to not breastfeed during the study or for 180 days after the last dose of study treatment\n* An untreated non-renal malignancy with the following exceptions:\n\n  * low risk prostate cancer on active surveillance (National Comprehensive Cancer Network \\[NCCN\\] very low\u002Flow risk)\n  * non-melanoma skin cancer\n* Any prior treated, non-renal malignancy except for those meeting the following characteristics:\n\n  * Treated stage I or II cancer from which the patient is currently in complete remission\n  * Stage III cancer in remission for \\> 2 years and is not receiving any current treatment\n  * A hematologic malignancy from which the patient is considered to be in complete remission\n* UTERINE FIBROIDS COHORT: Hormonal management ≤ 2 months of starting treatment. Including gonadotrophin releasing hormone (GnRH) analog, progestins or estrogen (pills or intrauterine devices), or ulipristal acetate\n* UTERINE FIBROIDS COHORT: GnRH analog usage ≤ 12 months of starting treatment\n* UTERINE FIBROIDS COHORT: History of uterine artery embolization\n* UTERINE FIBROIDS COHORT: Prior radiofrequency ablation to a target lesion\n* UTERINE FIBROIDS COHORT: History of MR guided focused ultrasound\n* UTERINE FIBROIDS COHORT: Myomectomy ≤ 1 year of starting therapy\n* UTERINE FIBROIDS COHORT: Concern for gynecologic malignancy\n* UTERINE FIBROIDS COHORT: Any Federation of Gynecology and Obstetrics (FIGO) 1 or FIGO 2 myomas requiring immediate treatment\n* UTERINE FIBROIDS COHORT: Planning pregnancy in the next 6 months\n* UTERINE FIBROIDS COHORT: History of endometrial ablation\n* UTERINE FIBROIDS COHORT: Hormonal intrauterine device (IUD) in place\n* CUTANEOUS LEIOMYOMAS COHORT: Willingness\u002Fability to have all cutaneous lesions completely removed","ALL","18 Years",{"count":19,"type":20},18,"ESTIMATED","INTERVENTIONAL",[23],"PHASE1","This phase I\u002FII trial studies the side effects and best dose of mercaptopurine, and to see how well it works in treating patients with hereditary leiomyomatosis and renal cell carcinoma (HLRCC). HLRCC is a rare inherited disorder that increases the risk of developing benign (not cancer) tumors of the skin and the uterus (leiomyomas) and malignant (cancer) tumors of the uterus (leiomyosarcoma) and the kidney. Mercaptopurine is in a class of medications called purine antagonists. It works by stopping the growth of cancer cells.",[26,27,28,29,30,31,32,33,34],"Advanced Kidney Carcinoma","Advanced Renal Cell Carcinoma","Hereditary Leiomyomatosis and Renal Cell Carcinoma","Metastatic Kidney Carcinoma","Metastatic Renal Cell Carcinoma","Skin Leiomyoma","Stage III Renal Cell Cancer AJCC v8","Stage IV Renal Cell Cancer AJCC v8","Uterine Corpus Leiomyoma","NOT_YET_RECRUITING","2026-08-04",{"date":38,"type":39},"2026-08-06","ACTUAL",{"date":41,"type":20},"2026-12-01",{"date":43,"type":20},"2035-12-01",{"name":45,"class":46},"Jonsson Comprehensive Cancer Center","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":16,"minAge":55,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":21,"phases":58,"briefSummary":60,"conditions":61,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":76},"100437840","phase-2-testing-of-bevacizumab-erlotinib-and-atezolizumab-in-combination-for-advanced-stage-kidney-cancer-100437840","NCT04981509","Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer","A Phase 2 Study of Bevacizumab, Erlotinib and Atezolizumab in Subjects With Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) Associated or Sporadic Papillary Renal Cell Cancer","Inclusion Criteria:\n\n* Patients must have:\n\n  * A diagnosis of HLRCC with a histologic or cytologic confirmation of RCC consistent with this diagnosis (Cohort 1) OR\n  * Cytologically or histologically confirmed sporadic\u002Fnon-HLRCC papillary renal cell carcinoma (presence of papillary component) (Cohort 2)\n* Patients must have advanced RCC with measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded for non-nodal lesions and short axis for nodal lesions) as \\>= 20 mm (\\>= 2 cm) by chest x-ray or as \\>= 10 mm (\\>= 1 cm) with CT scan, MRI, or calipers by clinical exam. To be considered pathologically enlarged and measurable, a lymph node must be \\>= 15 mm (\\>= 1.5 cm) in short axis\n* Patients must have received no more than two prior regimens targeting the VEGF pathway and no prior bevacizumab therapy in the metastatic\u002Fadvanced setting. No prior treatment with PD-1 or PD-L1 inhibitors in the metastatic\u002Fadvanced setting. No prior therapy is required for eligibility\n* Age \\>= 12 years\n* Eastern Cooperative Oncology Group (ECOG) performance status =\\\u003C 2 (Karnofsky \\>= 60%)\n* Absolute neutrophil count \\>= 1,000\u002FmcL\n* Platelets \\>= 100,000\u002FmcL\n* Total bilirubin =\\\u003C 1.5 x institutional upper limit of normal (ULN) (\\\u003C 3 x upper limit of reference range in patients with known\u002Fsuspected Gilbert's disease)\n* Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase \\[SGOT\\])\u002Falanine aminotransferase (ALT) (serum glutamate pyruvate transaminase \\[SGPT\\]) =\\\u003C 2.5 x institutional ULN (or =\\\u003C 5 x upper limit of reference range if considered to be related to liver or bone metastases by the principal investigator \\[PI\\])\n* Alkaline phosphatase =\\\u003C 2.5 x institutional ULN (or =\\\u003C 5 x upper limit of reference range if considered to be related to liver or bone metastases by the PI)\n\n  * Note: For pediatric patients (\\\u003C 18 years of age), ULN for alkaline phosphatase will be defined as 390 IU\u002FL for males and 320 IU\u002FL for females\n* Glomerular filtration rate (GFR) \\>= 30 mL\u002Fmin\u002F1.73 m\\^2\n\n  * Note: For pediatric patients (\\\u003C 18 years of age) the following creatinine thresholds will be utilized. Patients with a creatinine that exceeds this threshold will require further testing with a confirmation of GFR \\>= 40 as determined by either 24-hour urine collection or with radioisotope based nuclear medicine evaluation\n  * Age: 12 to \\\u003C 13 years; Maximum serum creatinine (mg\u002FdL): 1.2 (male); 1.2 (female)\n  * Age: 13 to \\\u003C 16 years; Maximum serum creatinine (mg\u002FdL): 1.5 (male); 1.4 (female)\n  * Age: 16 to \\\u003C 18 years; Maximum serum creatinine (mg\u002FdL): 1.7 (male); 1.4 (female)\n\n    * The threshold creatinine values in this table were derived from the Schwartz formula for estimating GFR, utilizing child length and stature data published by the Centers for Disease Control and Prevention (CDC)\n* Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with an undetectable viral load within 6 months are eligible for this trial\n* For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated\n* Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load\n* Patients with treated brain metastases are eligible if follow-up brain imaging after central nervous system (CNS)-directed therapy shows no evidence of progression\u002Frecurrence for \\>= 3 months and the patient no longer requires more than a physiologic dose of steroids\n* Patients does not have a prior or concurrent invasive malignancy; patients are eligible if a prior or concurrent invasive malignancy exists, but the natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen\n* Patients with a known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better\n* The effects of study drugs on the developing human fetus are unknown. For this reason, all women and men of childbearing potential must agree to use adequate contraception (including but not limited to abstinence, barrier methods, hormonal contraceptives \\[birth control pills, injections, or implants\\], intrauterine device \\[IUD\\], tubal ligation, vasectomy) prior to study entry and for 6 months after completion of study therapy. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, and 6 months after completion of study drugs administration\n* Subjects must provide archival tissue block or unstained tumor tissue or be willing to undergo biopsy to collect samples for retrospective central pathology review\n* The ability of subject or parent\u002Fguardian to understand and the willingness to sign a written informed consent document or subjects with impaired decision making capacity (IDMC) if they are represented by a legally authorized representative (LAR)\n\nExclusion Criteria:\n\n* Any prior systemic therapy to treat the patient's kidney cancer within 4 weeks or, if known, 5 half-lives of the prior agent (whichever is shorter) prior to cycle 1 day 1\n* Other prior therapies for kidney cancer: Radiotherapy \\\u003C 2 weeks prior to cycle 1, day 1\n* Major surgical procedure \\\u003C 28 days before cycle 1, day 1. Surgical wounds must be healed prior to starting therapy\n* Patients who have not recovered from adverse events due to prior systemic anti-cancer therapy (i.e., have residual toxicities \\> grade 1 of the Common Terminology Criteria for Adverse Events \\[CTCAE\\] version \\[v\\]5, pre-treatment baseline or to a level permitted under other sections of inclusion\u002Fexclusion criteria) with the exception of alopecia or electrolyte abnormalities that can be corrected to =\\\u003C grade 1 prior to treatment initiation\n* Treatment with any other investigational agent within 4 weeks prior to cycle 1, day 1\n* Treatment with systemic immunostimulatory agents (including, but not limited to, interferon \\[IFN\\]-alpha or interleukin \\[IL\\]-2) within 6 weeks prior to cycle 1, day 1\n* Treatment with systemic immunosuppressive medications (including, but not limited to, prednisone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor \\[anti-TNF\\] agents) within 2 weeks prior to cycle 1, day 1\n\n  * Patients who have received acute, low dose, systemic immunosuppressant medications (e.g., a one-time dose of dexamethasone for nausea or for purposes of pre-medication prior to radiology studies) may be enrolled\n  * The use of inhaled corticosteroids and mineralocorticoids (e.g., fludrocortisone) for patients with orthostatic hypotension or adrenocortical insufficiency is allowed\n* Hypercalcemia \\> grade 1 of the CTCAE v5 that is not corrected prior to treatment initiation\n* Patients taking bisphosphonate therapy for symptomatic hypercalcemia. Use of bisphosphonate therapy for other reasons (e.g., bone metastasis or osteoporosis) is allowed\n* History of autoimmune disease, including, but not limited to, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener's granulomatosis, Sjogren's syndrome, Bell's palsy, Guillain-Barre syndrome, multiple sclerosis, autoimmune thyroid disease, vasculitis, or glomerulonephritis\n\n  * Patients with a history of autoimmune hypothyroidism on a stable dose of thyroid replacement hormone may be eligible\n  * Patients with controlled type 1 diabetes mellitus on a stable insulin regimen may be eligible\n  * Patients with eczema, psoriasis, lichen simplex chronicus of vitiligo with dermatologic manifestations only (e.g., patients with psoriatic arthritis would be excluded) are permitted provided that they meet the following conditions:\n\n    * Patients with psoriasis must have a baseline ophthalmologic exam to rule out ocular manifestations\n    * Rash must cover less than 10% of body surface area (BSA)\n    * The disease is well controlled at baseline and only requiring low potency topical steroids (e.g., hydrocortisone 2.5%, hydrocortisone butyrate 0.1%, fluocinolone 0.01%, desonide 0.05%, alclometasone dipropionate 0.05%)\n    * No acute exacerbations of the underlying condition within the last 12 months (not requiring psoralen plus ultraviolet A radiation \\[PUVA\\], methotrexate, retinoids, biologic agents, oral calcineurin inhibitors; high potency or oral steroids)\n* History of idiopathic pulmonary fibrosis, pneumonitis (including drug-induced), organizing pneumonia (i.e., bronchiolitis obliterans, cryptogenic organizing pneumonia, etc.), or evidence of active pneumonitis. History of radiation pneumonitis in the radiation field (fibrosis) is permitted\n* Patients with untreated latent or active tuberculosis (TB) are excluded\n* Severe infections within 4 weeks prior to cycle 1, day 1, including, but not limited to, hospitalization for complications of infection, bacteremia, or severe pneumonia\n* Administration of a live, attenuated vaccine within 4 weeks before cycle 1, day 1 or anticipation that such a live, attenuated vaccine will be required during the study and up to 5 months after the last dose of atezolizumab\n\n  * NOTE: Seasonal influenza vaccines for injection are generally inactivated flu vaccines and are allowed; however intranasal influenza vaccines (e.g., Flu-Mist) are live attenuated vaccines and are not allowed. Influenza vaccination should be given during influenza season only (approximately October to March)\n* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection requiring intravenous antibiotics, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements\n* Poorly controlled hypertension with at least 2 occasions of elevated blood pressure separated by a 24-hour periodd within a week before treatment initiation, despite optimal medical management. (Adults: resting systolic blood pressure greater than 140 mmHg or diastolic blood pressure greater than 90 mmHg. Pediatric \\[\\\u003C 18 years old\\]: Blood pressure \\[BP\\] \\>= the 95th percentile for age, height, and sex). History of hypertensive crisis or hypertensive encephalopathy\n* Patients with prior allogeneic bone marrow transplantation or prior solid organ transplantation\n* History of anaphylactic or severe allergic reactions attributed to compounds of similar chemical or biologic composition to the study agents\n* Patients with myocardial infarction, gastrointestinal (GI) perforation\u002Ffistula, intraabdominal abscess, or cerebrovascular accidents within 6 months before cycle 1, day 1\n* Documented baseline proteinuria \\> 1000 mg\u002Fday on 24-hour urine collection. Only patients with 1+ or greater proteinuria on urinalysis (UA) and a spot urine protein:creatinine ratio of \\> 0.5 will undergo a 24-hour urine collection for quantitation of proteinuria\n* Pregnant women are excluded from this study because study drugs may have the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with study drugs, breastfeeding should be discontinued if the mother is treated with study drugs\n* Serious, non-healing wound or ulcer; bone fracture within 3 months prior to treatment initiation\n* Concomitant therapy with systemic medications or herbal supplements that are known strong inhibitors or inducers of CYP450 3A4, or strong CYP1A2 inducers. To determine the impact of a concomitant drug on CYP enzymes see the FDA-approved product labeling and\u002For tertiary compendia (e.g., Inhibitors and Inducers of Cytochrome P450 Enzymes)\n* Patients who use tobacco or nicotine products and cannot stop their use of these products for the duration of study treatment\n* Significant vascular disease (e.g., aortic aneurysm requiring surgical repair or recent arterial thrombosis) within 6 months prior to cycle 1, day 1\n* History of or active hemoptysis within 1 month prior to cycle 1 day 1\n* History of grade \\>= 4 venous thromboembolism\n* History or evidence of inherited bleeding diathesis or significant coagulopathy at risk of bleeding (i.e., in the absence of therapeutic anticoagulation)\n* Current or recent (\\\u003C 10 days prior to initiation of study treatment) use of aspirin (\\> 325 mg\u002Fday), or clopidogrel (\\> 75 mg\u002Fday)\n\n  * Note: The use of full-dose oral or parenteral anticoagulants for therapeutic purpose is permitted as long as the International Normalized Ratio (INR) and\u002For a partial thromboplastin time (PTT) is within therapeutic limits (according to institution standards) within 7 days prior to initiation of study treatment and the patient has been on a stable dose of anticoagulants for \\>= 2 weeks prior to initiation of study treatment. Prophylactic use of anticoagulants is allowed. However, the use of direct oral anticoagulant therapies such as dabigatran (Pradaxa \\[registered trademark\\]) and rivaroxaban (Xarelto \\[registered trademark\\]) may be used per PI discretion","12 Years",{"count":57,"type":20},65,[59],"PHASE2","This phase II trial studies the effects of combination therapy with bevacizumab, erlotinib, and atezolizumab in treating patients with hereditary leiomyomatosis and kidney cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Bevacizumab is in a class of medications called antiangiogenic agents. They work by stopping the formation of blood vessels that bring oxygen and nutrients to tumors. This may slow the growth and spread of tumors. Erlotinib is in a class of medications called kinase inhibitors. It works by blocking the action of a protein called EGFR that signals cancer cells to multiply. This helps slow or stop the spread of cancer cells. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Combination therapy with bevacizumab, erlotinib, and atezolizumab may stabilize or shrink advanced hereditary leiomyomatosis and kidney cancer.",[28,62,63,64,32,33],"Papillary Renal Cell Carcinoma","Renal Cell Carcinoma","Sporadic Papillary Renal Cell Carcinoma","RECRUITING","2026-07-30",{"date":68,"type":39},"2026-07-31",{"date":70,"type":39},"2022-06-10",{"date":72,"type":20},"2027-12-31",{"name":74,"class":75},"National Cancer Institute (NCI)","NIH",13]